Inspirna (formerly RGENIX) adds Dieter Weinand to its Board of Directors as Chairman

– USA, NY –  Inspirna, Inc. (formerly RGENIX), a clinical-stage biopharmaceutical company developing first-in-class small molecule and biologic cancer therapeutics, today announced the appointment of Dieter Weinand to its Board of Directors as Chairman.

The company also announced changing its Corporate name from Rgenix to Inspirna.

“We are thrilled to welcome Dieter to Inspirna. A seasoned executive in the pharma and biotech industries, his insight will be invaluable as we work to advance our drug candidates through the clinic. He has guided companies across various therapeutic areas, including oncology, from the clinical phase through launch and commercialization, and we look forward to benefitting from his expertise.” said CEO, Dr. Masoud Tavazoie.

He added: “Given the recent progress made advancing our novel oral small molecule programs RGX-202 and RGX-104 through the clinic, and in anticipation of executing on upcoming milestones, we knew this was an opportune time to align our company name with the science on which our pipeline is based. Our new name and logo combine our desire to inspire the development of new cancer medicines with our proprietary RNA-based target discovery platform, and we believe this name now more closely aligns with our mission to develop novel therapeutics that can uniquely benefit patients with difficult to treat cancers.”

About Dieter Weinand

Dieter Weinand, formerly CEO of Bayer Pharma AG, brings over 30 years of experience across the pharmaceutical and biotechnology industries.

“I am delighted to be joining the Inspirna Board of Directors as Chairman at this time of tremendous progress for the Company,” said Mr. Weinand. “I am impressed with the clinical and preclinical work the Company has completed thus far and was drawn to the RNA technology on which the pipeline is founded, which I believe has the potential to provide new treatment options for patients with cancer.”

Before his most recent role as CEO of Bayer Pharma AG, Mr. Weinand held senior leadership positions at Pfizer, Bristol-Myers Squibb, and Sanofi, with responsibilities ranging from management and strategy to operations and commercialization. He has led the launch and marketing of numerous products, including those in primary care, specialty care, and oncology.

Mr. Weinand sits on several boards as Chairman, including Replimune, ForeBio, Mnemo, and ZielBioPharma. Additionally, he is a director of FieldTrip Health.

Mr. Weinand earned his M.S. in pharmacology and toxicology from Long Island University and his B.A. in biology from Concordia College.

About Inspirna

Inspirna, Inc., is a privately-held clinical-stage biopharmaceutical company focused on the discovery and development of novel cancer drugs that target key pathways in cancer progression. The company is pursuing several first-in-class drug candidates to treat cancers of high unmet need. Inspirna identifies novel cancer targets using its RNA-based target discovery platform, RNA-DRIVEr, which was originally developed by Inspirna’s scientific co-founders at The Rockefeller University and exclusively licensed to Inspirna. The Company brings together distinguished scientific founders, a seasoned board of directors, and a leadership team comprised of experienced drug developers. The Company is funded by leading biotechnology investors, including Novo Holdings A/S, Sofinnova Partners, Lepu Holdings Limited, Sixty Degree Capital, K2 HealthVentures, Oceanpine Capital, WuXi PharmaTech Healthcare Fund I, LP, Alexandria Venture Investments, LLC, Exor Seeds, and the Partnership Fund for New York City.

For more information: https://rgenix.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.